Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

Phase 2

Active, not recruiting

Conditions: Squamous Cell Carcinoma of Head and Neck

Interventions: Drug: Atezolizumab
Drug: Tiragolumab
Drug: Placebo

First Posted Date: 2020-12-14

Last Posted Date: 2025-03-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 123

Registration Number: NCT04665843

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇨🇿
Fakultni nemocnice v Motole, Praha 5, Czechia
🇫🇷
Centre Francois Baclesse, Caen, France

and more 41 locations

A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

Phase 2

Active, not recruiting

Conditions: Gastric Cancer
Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Atezolizumab
Drug: Trastuzumab
Drug: Capecitabine
Drug: Oxaliplatin

First Posted Date: 2020-12-10

Last Posted Date: 2025-04-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 42

Registration Number: NCT04661150

Locations: 🇨🇳
West China Hospital, Sichuan University, Chengdu, China
🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, China

and more 5 locations

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy

Phase 3

Active, not recruiting

Conditions: Muscle-invasive Bladder Cancer

Interventions: Drug: Atezolizumab
Other: Placebo
Device: Signatera

First Posted Date: 2020-12-09

Last Posted Date: 2025-04-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 761

Registration Number: NCT04660344

Locations: 🇹🇷
Medikal Park Samsun, Samsun, Turkey
🇧🇷
Beneficencia Portuguesa de Sao Paulo, São Paulo, Brazil
🇺🇸
Rocky Mountain Cancer Center - Denver, Littleton, Colorado, United States

and more 164 locations

A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Phase 3

Completed

Conditions: Neuromyelitis Optica Spectrum Disorder

Interventions: Drug: satralizumab
Drug: azathioprine (AZA)
Drug: mycophenolate mofetil (MMF)
Drug: oral corticosteroids

First Posted Date: 2020-12-09

Last Posted Date: 2024-12-27

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 119

Registration Number: NCT04660539

Locations: 🇺🇸
Jefferson Hospital For Neuroscience; Jefferson Neurology Associates, Philadelphia, Pennsylvania, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

and more 50 locations

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2

Completed

Conditions: Lymphoma, Large B-Cell, Diffuse

Interventions: Drug: Rituximab IV
Drug: Rituximab SC
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Paracetamol
Drug: Diphenhydramine hydrochloride or alternative antihistamine

First Posted Date: 2020-12-09

Last Posted Date: 2023-10-12

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 50

Registration Number: NCT04660799

Locations: 🇨🇳
The First Hospital of Jilin University, Changchun City, China
🇨🇳
Peking University Third Hospital, Beijing, China
🇨🇳
Fujian Provincial Cancer Hospital, Fuzhou City, China

and more 5 locations

A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: Obinutuzumab
Drug: Glofitamab
Drug: Tocilizumab

First Posted Date: 2020-12-08

Last Posted Date: 2024-01-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 30

Registration Number: NCT04657302

Locations: 🇨🇳
Tianjin Cancer Hospital, Tianjin, China
🇨🇳
Cancer Center, Sun Yat-sen University of Medical Sciences; Department of Medical Oncology, Guangzhou City, China
🇨🇳
Beijing Cancer Hospital, Beijing, China

and more 3 locations

A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

Phase 3

Recruiting

Conditions: Neovascular Age-related Macular Degeneration (nAMD)

Interventions: Drug: Ranibizumab
Device: Port Delivery System with Ranibizumab

First Posted Date: 2020-12-08

Last Posted Date: 2025-05-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 442

Registration Number: NCT04657289

Locations: 🇮🇱
Rabin MC, Petach Tikva, Israel
🇮🇱
Kaplan Medical Center, Rehovot, Israel
🇮🇱
Tel Aviv Sourasky MC, Tel Aviv, Israel

and more 119 locations

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition

Phase 3

Active, not recruiting

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Interventions: Drug: Crovalimab

First Posted Date: 2020-12-04

Last Posted Date: 2025-05-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 51

Registration Number: NCT04654468

Locations: 🇨🇳
West China Hospital, Sichuan University, Chengdu City, China
🇨🇳
Institute of Hematology and Hospital of Blood Disease, Tianjin City, China
🇨🇳
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, China

and more 1 locations

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

Phase 2

Terminated

Conditions: Melanoma
Pancreatic Neoplasms
Ovarian Neoplasms
Brain Neoplasms
Thyroid Neoplasms
Neuroendocrine Tumors
Salivary Gland Neoplasms
Digestive System Diseases
Neoplasms
Cholangiocarcinoma

Interventions: Drug: Alectinib

First Posted Date: 2020-11-25

Last Posted Date: 2023-08-07

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1

Registration Number: NCT04644315

Locations: 🇺🇸
Science 37-Cannon; Dept 002-Cannon, Culver City, California, United States
🇺🇸
Science 37-Basem; Dept 004- Basem, Culver City, California, United States
🇺🇸
Science 37, Inc, Culver City, California, United States

and more 4 locations

A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.

Phase 1

Terminated

Conditions: Solid Tumors

Interventions: Drug: RO7296682
Drug: Atezolizumab

First Posted Date: 2020-11-24

Last Posted Date: 2025-05-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 49

Registration Number: NCT04642365

Locations: 🇦🇺
Peter Maccallum Cancer Institute, Melbourne, Victoria, Australia
🇪🇸
Hospital Clinico Universitario de Valencia, Valencia, Spain
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy